JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garrido, M. J.
Right arrow Articles by Trocóniz, I. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garrido, M. J.
Right arrow Articles by Trocóniz, I. F.

Vol. 288, Issue 1, 179-187, January 1999

Altered Plasma and Brain Disposition and Pharmacodynamics of Methadone in Abstinent Rats

María J. Garrido, Marta Valle, Rosario Calvo and Iñaki F. Trocóniz

Department of Pharmacology, School of Medicine, University of Basque Country, Leioa (M.J.G., M.V., R.C.); and Department of Pharmacy, School of Pharmacy, University of Navarra, Pamplona (I.F.T.), Spain

The pharmacokinetics and pharmacodynamics of methadone were investigated in control and abstinent rats. Minipumps filled with saline (control group) or saline-morphine (abstinent group) solutions were used to induce physical dependence. Solutions were delivered continuously by minipumps for 6 days. The physical dependence was evaluated 12 h after minipump removal by measuring specific withdrawal signs. Animals from the abstinent group showed clear withdrawal signs such as hostility on handling and weight loss. Plasma and brain disposition and pharmacodynamics of methadone were evaluated after a 0.35 mg/kg i.v. bolus dose administered 12 h after minipump removal. Plasma clearance, distribution clearance, and volume of distribution at steady-state were significantly decreased (P < 0.05) in the abstinent group. Plasma levels of alpha 1-acid glycoprotein and plasma protein binding were significantly increased (P < 0.05) in the abstinent group. The estimates of pharmacokinetic parameters based on unbound plasma concentrations did not differ between groups, with the sole exception of the unbound apparent volume of distribution. The access of methadone to the brain was significantly faster (P < 0.05) in the abstinent group, although the extent of distribution in the brain was diminished in comparison with the control group. Analgesia recorded with tail-flick was used as the pharmacodynamic endpoint. Analgesic response and effect compartment concentrations of methadone were related by the sigmoidal Emax model. Estimates of C50 [steady-state plasma concentrations eliciting half of maximum effect (Emax)]] based on unbound concentrations did not differ between groups. On the other hand, the estimate of Emax had decreased by 65% in the abstinent group.


0022-3565/99/2881-0179$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. K. Melichar, S. P. Hume, T. M. Williams, M. R. C. Daglish, L. G. Taylor, R. Ahmad, A. L. Malizia, D. J. Brooks, J. S. Myles, A. Lingford-Hughes, et al.
Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 309 - 315.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. J. Valenzano, W. Miller, Z. Chen, S. Shan, G. Crumley, S. F. Victory, E. Davies, J.-C. Huang, N. Allie, S. J. Nolan, et al.
DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: I. In Vitro Pharmacological Characterization and Pharmacokinetic Properties
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 783 - 792.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Valle, M. J. Garrido, J. M. Pavón, R. Calvo, and I. F. Trocóniz
Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)-O-Desmethyltramadol and (-)-O-Desmethyltramadol, in Rats
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 646 - 653.
[Abstract] [Full Text]


Home page
Antimicrob. Agents Chemother.Home page
I. Echevarría, C. Barturen, M. J. Renedo, I. F. Trocóniz, and M. C. Dios-Viéitez
Comparative Pharmacokinetics, Tissue Distributions, and Effects on Renal Function of Novel Polymeric Formulations of Amphotericin B and Amphotericin B-Deoxycholate in Rats
Antimicrob. Agents Chemother., April 1, 2000; 44(4): 898 - 904.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.